1.01
price down icon4.13%   -0.03
 
loading
Ocugen Inc stock is traded at $1.01, with a volume of 2.56M. It is down -4.13% in the last 24 hours and down -8.52% over the past month. Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
2.56M
Relative Volume:
0.47
Market Cap:
$294.95M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.7407
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-13.30%
1M Performance:
-8.52%
6M Performance:
+40.44%
1Y Performance:
-45.51%
1-Day Range:
Value
$0.9923
$1.06
1-Week Range:
Value
$0.9923
$1.19
52-Week Range:
Value
$0.515
$1.80

Ocugen Inc Stock (OCGN) Company Profile

Name
Name
Ocugen Inc
Name
Phone
484-328-4701
Name
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
Employee
95
Name
Twitter
@Ocugen
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
OCGN's Discussions on Twitter

Compare OCGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OCGN
Ocugen Inc
1.01 330.00M 0 -63.08M -72.53M -0.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
466.55 123.00B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
551.01 59.66B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.59 41.84B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
569.88 33.98B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.26 27.67B 3.81B -644.79M -669.77M -6.24

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-15-24 Initiated Maxim Group Buy
Mar-01-23 Upgrade Chardan Capital Markets Neutral → Buy
Aug-23-22 Initiated Mizuho Buy
Jun-15-22 Resumed ROTH Capital Buy
Jun-02-22 Initiated Cantor Fitzgerald Overweight
Jul-26-21 Initiated Noble Capital Markets Outperform
Jun-11-21 Downgrade ROTH Capital Buy → Neutral
May-07-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21 Downgrade Chardan Capital Markets Buy → Neutral
Feb-04-21 Upgrade H.C. Wainwright Neutral → Buy
View All

Ocugen Inc Stock (OCGN) Latest News

pulisher
07:25 AM

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - Ocugen

07:25 AM
pulisher
06:31 AM

Ocugen to Host Conference Call on Friday, August 1 at 8:30 - GlobeNewswire

06:31 AM
pulisher
06:30 AM

Ocugen Earnings: Gene Therapy Pioneer to Report Q2 2025 Results August 1 - Stock Titan

06:30 AM
pulisher
Jul 16, 2025

Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail

Jul 16, 2025
pulisher
Jul 10, 2025

Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Building Biotech Champions: Cultivating Breakthroughs In A Dynamic Field - Life Science Leader

Jul 10, 2025
pulisher
Jul 09, 2025

OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty - ACCESS Newswire

Jul 09, 2025
pulisher
Jul 01, 2025

Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid - Investing.com

Jul 01, 2025
pulisher
Jun 29, 2025

How did OCGN's Q4 earnings surprise impact its annual performance? - AInvest

Jun 29, 2025
pulisher
Jun 25, 2025

After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals

Jun 25, 2025
pulisher
Jun 24, 2025

Ocugen stock steady as H.C. Wainwright reiterates buy rating By Investing.com - Investing.com South Africa

Jun 24, 2025
pulisher
Jun 23, 2025

Major Biotech Merger: Carisma and OrthoCellix Unite to Advance Revolutionary Knee Cartilage Treatment - Stock Titan

Jun 23, 2025
pulisher
Jun 19, 2025

Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN

Jun 19, 2025
pulisher
Jun 18, 2025

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Ocugen to Release New Investor Presentation - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com

Jun 16, 2025
pulisher
Jun 13, 2025

Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 - Ocugen

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN

Jun 10, 2025
pulisher
Jun 09, 2025

Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Ocugen signs term sheet for Korean licensing of OCU400 gene therapy - Modern Retina

Jun 09, 2025
pulisher
Jun 08, 2025

Ocugen signs license deal with Korean company for gene therapy - MSN

Jun 08, 2025
pulisher
Jun 08, 2025

Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Ocugen Signs License Agreement for OCU400 in Korea - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks

Jun 05, 2025

Ocugen Inc Stock (OCGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.00
price up icon 3.69%
$35.60
price down icon 2.49%
$104.55
price down icon 0.21%
$28.27
price up icon 16.05%
$112.08
price down icon 0.37%
biotechnology ONC
$279.16
price up icon 3.51%
Cap:     |  Volume (24h):